
Health
Biomarkers’ slow march to surrogate endpoints advances
The slow march of clinical biomarkers to become surrogate endpoints promises to accelerate drug development and patient…
Marcus Rivera·
3 articles

The slow march of clinical biomarkers to become surrogate endpoints promises to accelerate drug development and patient…

Novo Nordisk and OpenAI have formed a groundbreaking AI partnership to accelerate the development of new weight loss dru…

Tonix Pharmaceuticals announced the groundbreaking publication of TONMYA pharmacokinetics data in a peer-reviewed journa…